Myelodysplastic syndrome looks like a tough nut to crack and still remains a high unmet need. Here's a few drugs that have failed over recent years. Hopefully we have something that can help.
https://www.fiercebiotech.com/biotech/novartis-calls-time-tim-3-axing-cancer-candidate-after-phase-3-flop
https://www.biospace.com/aprea-therapeutics-crashes-with-phase-iii-flop-of-cancer-treatment
https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.64M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| SNT (ASX) Chart |
Day chart unavailable